Cerus, and a subsidiary of Grifols have announced that the two companies have entered into an agreement to collaborate on the development of red blood cell treatment sets for use in the Intercept Blood System.
Under this agreement, Grifols has to provide their technical expertise and resources for the development of commercial kit manufacturing, and also establishes joint commitment to a future commercial manufacturing contract.
The Intercept red blood cell system, currently in phase I trials, is being developed to inactivate a broad range of pathogens expected to contaminate donated blood.
Claes Glassell, President and CEO of Cerus Corporation, said: “Grifols’ demonstrated expertise in blood collection sets is a significant asset to the Intercept red cell program.”
Albert Grifols, General Manager of Laboratorios Grifols, said: “We are pleased to further strengthen our relationship with Cerus after our success with the Intercept platelet system.